한글목차

희귀의약품 시장 - 조사 범위

TMR의 희귀의약품 세계 시장 조사 보고서는 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측연도로 하여 2018년부터 2034년까지 세계 희귀의약품 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 희귀의약품 시장의 연평균 성장률(CAGR%)을 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 희귀의약품 시장을 이해했습니다.

이 보고서는 세계 희귀의약품 시장 경쟁 구도를 심층적으로 분석합니다. 세계 희귀의약품 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에서 다루는 세계 희귀의약품 시장 기업의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 서론
• 시장 개요
• 시장 역학
• 세계 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

• 파이프라인 분석
• 주요 제품/브랜드 분석
• 주요 M&A
• COVID-19 팬데믹의 산업에 대한 영향

제6장 세계 시장 분석과 예측 : 질환 유형별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 질환 유형별, 2020-2034년
  • 종양
  • 소화기
  • 호흡기
  • 신경
  • 혈액
  • 순환기
  • 대사질환
  • 내분비학
  • 감염증
  • 기타
• 시장의 매력 : 질환 유형별

제7장 세계 시장 분석과 예측 : 지표별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 지표별, 2020년-2034년
  • 생물학적 제제
  • 비생물학적 제제
• 시장의 매력 : 지표별

제8장 세계 시장 분석과 예측 : 유통 채널별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 유통 채널별, 2020년-2034년
  • 병원 약국
  • 전문 약국
  • 소매 약국
  • 기타
• 시장의 매력 : 유통 채널별

제9장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 매출 예측 : 지역별, 2020-2034
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 전망

제14장 중동 및 아프리카 시장 분석과 전망

제15장 경쟁 구도

• 시장 경쟁 매트릭스(기업 Tier별·기업 규모별)
• 시장 점유율 분석 : 기업별(2023년)
• 기업 개요
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Alexion Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Daiichi Sankyo Company Limited
  • Bayer AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Biogen, Inc.
  • Shire plc
  • Amgen, Inc.

영문목차

Orphan Drugs Market - Scope of Report

TMR's report on the global orphan drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global orphan drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global orphan drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the orphan drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global orphan drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global orphan drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global orphan drugs market.

The report delves into the competitive landscape of the global orphan drugs market. Key players operating in the global orphan drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global orphan drugs market profiled in this report.

Key Questions Answered in Global orphan drugs Market Report:

• What is the sales/revenue generated by orphan drugs across all regions during the forecast period?
• What are the opportunities in the global orphan drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Orphan Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global orphan drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global orphan drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global orphan drugs market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Orphan Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Orphan Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Orphan Drugs Market Analysis and Forecast, by Disease Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Disease Type, 2020-2034
  • 6.3.1. Oncology
  • 6.3.2. Gastrointestinal
  • 6.3.3. Pulmonary
  • 6.3.4. Neurology
  • 6.3.5. Hematology
  • 6.3.6. Cardiovascular
  • 6.3.7. Metabolic Disorders
  • 6.3.8. Endocrinology
  • 6.3.9. Infectious Diseases
  • 6.3.10. Others
• 6.4. Market Attractiveness, by Disease Type

7. Global Orphan Drugs Market Analysis and Forecast, by Indicator

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Indicator, 2020-2034
  • 7.3.1. Biologic
  • 7.3.2. Non-biologic
• 7.4. Market Attractiveness, by Indicator

8. Global Orphan Drugs Market Analysis and Forecast, By Distribution Channel

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, By Distribution Channel, 2020-2034
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Specialty Pharmacies
  • 8.3.3. Retail Pharmacies
  • 8.3.4. Others
• 8.4. Market Attractiveness, By Distribution Channel

9. Global Orphan Drugs Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2020-2034
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness, by Region

10. North America Orphan Drugs Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Disease Type, 2020-2034
  • 10.2.1. Oncology
  • 10.2.2. Gastrointestinal
  • 10.2.3. Pulmonary
  • 10.2.4. Neurology
  • 10.2.5. Hematology
  • 10.2.6. Cardiovascular
  • 10.2.7. Metabolic Disorders
  • 10.2.8. Endocrinology
  • 10.2.9. Infectious Diseases
  • 10.2.10. Others
• 10.3. Market Attractiveness, by Disease Type
• 10.4. Market Value Forecast, by Indicator, 2020-2034
  • 10.4.1. Biologic
  • 10.4.2. Non-biologic
• 10.5. Market Attractiveness, by Indicator
• 10.6. Market Value Forecast, By Distribution Channel, 2020-2034
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Specialty Pharmacies
  • 10.6.3. Retail Pharmacies
  • 10.6.4. Others
• 10.7. Market Attractiveness, By Distribution Channel
• 10.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 10.8.1. U.S.
  • 10.8.2. Canada
• 10.9. Market Attractiveness Analysis
  • 10.9.1. By Disease Type
  • 10.9.2. By Indicator
  • 10.9.3. By Distribution Channel
  • 10.9.4. By Country

11. Europe Orphan Drugs Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Disease Type, 2020-2034
  • 11.2.1. Oncology
  • 11.2.2. Gastrointestinal
  • 11.2.3. Pulmonary
  • 11.2.4. Neurology
  • 11.2.5. Hematology
  • 11.2.6. Cardiovascular
  • 11.2.7. Metabolic Disorders
  • 11.2.8. Endocrinology
  • 11.2.9. Infectious Diseases
  • 11.2.10. Others
• 11.3. Market Attractiveness, by Disease Type
• 11.4. Market Value Forecast, by Indicator, 2020-2034
  • 11.4.1. Biologic
  • 11.4.2. Non-biologic
• 11.5. Market Attractiveness, by Indicator
• 11.6. Market Value Forecast, By Distribution Channel, 2020-2034
  • 11.6.1. Hospital Pharmacies
  • 11.6.2. Specialty Pharmacies
  • 11.6.3. Retail Pharmacies
  • 11.6.4. Others
• 11.7. Market Attractiveness, By Distribution Channel
• 11.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.8.1. Germany
  • 11.8.2. U.K.
  • 11.8.3. France
  • 11.8.4. Italy
  • 11.8.5. Spain
  • 11.8.6. Rest of Europe
• 11.9. Market Attractiveness Analysis
  • 11.9.1. By Disease Type
  • 11.9.2. By Indicator
  • 11.9.3. By Distribution Channel
  • 11.9.4. By Country/Sub-region

12. Asia Pacific Orphan Drugs Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Disease Type, 2020-2034
  • 12.2.1. Oncology
  • 12.2.2. Gastrointestinal
  • 12.2.3. Pulmonary
  • 12.2.4. Neurology
  • 12.2.5. Hematology
  • 12.2.6. Cardiovascular
  • 12.2.7. Metabolic Disorders
  • 12.2.8. Endocrinology
  • 12.2.9. Infectious Diseases
  • 12.2.10. Others
• 12.3. Market Attractiveness, by Disease Type
• 12.4. Market Value Forecast, by Indicator, 2020-2034
  • 12.4.1. Biologic
  • 12.4.2. Non-biologic
• 12.5. Market Attractiveness, by Indicator
• 12.6. Market Value Forecast, By Distribution Channel, 2020-2034
  • 12.6.1. Hospital Pharmacies
  • 12.6.2. Specialty Pharmacies
  • 12.6.3. Retail Pharmacies
  • 12.6.4. Others
• 12.7. Market Attractiveness, By Distribution Channel
• 12.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.8.1. China
  • 12.8.2. Japan
  • 12.8.3. India
  • 12.8.4. Australia & New Zealand
  • 12.8.5. Rest of Asia Pacific
• 12.9. Market Attractiveness Analysis
  • 12.9.1. By Disease Type
  • 12.9.2. By Indicator
  • 12.9.3. By Distribution Channel
  • 12.9.4. By Country/Sub-region

13. Latin America Orphan Drugs Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Disease Type, 2020-2034
  • 13.2.1. Oncology
  • 13.2.2. Gastrointestinal
  • 13.2.3. Pulmonary
  • 13.2.4. Neurology
  • 13.2.5. Hematology
  • 13.2.6. Cardiovascular
  • 13.2.7. Metabolic Disorders
  • 13.2.8. Endocrinology
  • 13.2.9. Infectious Diseases
  • 13.2.10. Others
• 13.3. Market Attractiveness, by Disease Type
• 13.4. Market Value Forecast, by Indicator, 2020-2034
  • 13.4.1. Biologic
  • 13.4.2. Non-biologic
• 13.5. Market Attractiveness, by Indicator
• 13.6. Market Value Forecast, By Distribution Channel, 2020-2034
  • 13.6.1. Hospital Pharmacies
  • 13.6.2. Specialty Pharmacies
  • 13.6.3. Retail Pharmacies
  • 13.6.4. Others
• 13.7. Market Attractiveness, By Distribution Channel
• 13.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.8.1. Brazil
  • 13.8.2. Mexico
  • 13.8.3. Rest of Latin America
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Disease Type
  • 13.9.2. By Indicator
  • 13.9.3. By Distribution Channel
  • 13.9.4. By Country/Sub-region

14. Middle East & Africa Orphan Drugs Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Disease Type, 2020-2034
  • 14.2.1. Oncology
  • 14.2.2. Gastrointestinal
  • 14.2.3. Pulmonary
  • 14.2.4. Neurology
  • 14.2.5. Hematology
  • 14.2.6. Cardiovascular
  • 14.2.7. Metabolic Disorders
  • 14.2.8. Endocrinology
  • 14.2.9. Infectious Diseases
  • 14.2.10. Others
• 14.3. Market Attractiveness, by Disease Type
• 14.4. Market Value Forecast, by Indicator, 2020-2034
  • 14.4.1. Biologic
  • 14.4.2. Non-biologic
• 14.5. Market Attractiveness, by Indicator
• 14.6. Market Value Forecast, By Distribution Channel, 2020-2034
  • 14.6.1. Hospital Pharmacies
  • 14.6.2. Specialty Pharmacies
  • 14.6.3. Retail Pharmacies
  • 14.6.4. Others
• 14.7. Market Attractiveness, By Distribution Channel
• 14.8. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.8.1. GCC Countries
  • 14.8.2. South Africa
  • 14.8.3. Rest of Middle East & Africa
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Disease Type
  • 14.9.2. By Indicator
  • 14.9.3. By Distribution Channel
  • 14.9.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Novartis AG
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Bristol-Myers Squibb Company
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Celgene Corporation
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. F. Hoffmann-La Roche Ltd.
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Pfizer, Inc.
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Sanofi S.A.
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Alexion Pharmaceuticals, Inc.
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. SWOT Analysis
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Eli Lilly and Company
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. SWOT Analysis
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Novo Nordisk A/S
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. SWOT Analysis
    • 15.3.9.5. Strategic Overview
  • 15.3.10. AstraZeneca plc
    • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. SWOT Analysis
    • 15.3.10.5. Strategic Overview
  • 15.3.11. Eisai Co., Ltd.
    • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.11.2. Product Portfolio
    • 15.3.11.3. Financial Overview
    • 15.3.11.4. SWOT Analysis
    • 15.3.11.5. Strategic Overview
  • 15.3.12. Daiichi Sankyo Company Limited
    • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.12.2. Product Portfolio
    • 15.3.12.3. Financial Overview
    • 15.3.12.4. SWOT Analysis
    • 15.3.12.5. Strategic Overview
  • 15.3.13. Bayer AG
    • 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.13.2. Product Portfolio
    • 15.3.13.3. Financial Overview
    • 15.3.13.4. SWOT Analysis
    • 15.3.13.5. Strategic Overview
  • 15.3.14. GlaxoSmithKline plc
    • 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.14.2. Product Portfolio
    • 15.3.14.3. Financial Overview
    • 15.3.14.4. SWOT Analysis
    • 15.3.14.5. Strategic Overview
  • 15.3.15. Merck & Co., Inc.
    • 15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.15.2. Product Portfolio
    • 15.3.15.3. Financial Overview
    • 15.3.15.4. SWOT Analysis
    • 15.3.15.5. Strategic Overview
  • 15.3.16. Johnson & Johnson
    • 15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.16.2. Product Portfolio
    • 15.3.16.3. Financial Overview
    • 15.3.16.4. SWOT Analysis
    • 15.3.16.5. Strategic Overview
  • 15.3.17. Biogen, Inc.
    • 15.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.17.2. Product Portfolio
    • 15.3.17.3. Financial Overview
    • 15.3.17.4. SWOT Analysis
    • 15.3.17.5. Strategic Overview
  • 15.3.18. Shire plc
    • 15.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.18.2. Product Portfolio
    • 15.3.18.3. Financial Overview
    • 15.3.18.4. SWOT Analysis
    • 15.3.18.5. Strategic Overview
  • 15.3.19. Amgen, Inc.
    • 15.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.19.2. Product Portfolio
    • 15.3.19.3. Financial Overview
    • 15.3.19.4. SWOT Analysis
    • 15.3.19.5. Strategic Overview